Related Experiment Videos
[Calcium inhibitors: effects on cerebral blood flow and intracranial pressure]
Insights
Calcium entry blockers (CEB) offer cerebrovascular benefits, particularly in subarachnoid hemorrhage for vasospasm prevention. Their efficacy in established vasospasm and focal ischemia remains less clear, requiring cautious use.
Area of Science:
- Pharmacology
- Neurology
- Cardiovascular Diseases
Context:
- Calcium entry blockers (CEB) are increasingly utilized in neurology and intensive care.
- CEB demonstrate potent cerebrovascular vasodilation, especially post-KCL induced vasoconstriction.
- Their effects on cerebrovascular response to CO2 and systemic hypotension are significant.
Purpose:
- To evaluate the efficacy and safety of CEB in neurological conditions, particularly brain ischemia.
- To assess the role of CEB in vasospasm prevention and treatment.
- To understand the impact of CEB on intracranial pressure.
Summary:
- CEB are effective in preventing vasospasm after subarachnoid hemorrhage.
- Their benefit is less evident once vasospasm is established.
- Data on CEB in focal cerebral ischemia are limited, warranting cautious application.
- CEB may increase intracranial pressure, influenced by the neurological condition.
Impact:
- CEB represent a significant advancement in managing cerebrovascular disorders.
- Understanding CEB's selective cerebral effects aids in targeted therapeutic strategies.
- Further research is needed to clarify CEB's role in specific ischemic scenarios.
Abstract:
Calcium entry blockers (CEB) have been a major advance in pharmacologic research in the last decade, especially in cardiovascular diseases. In neurology and intensive care, prescription of CEB seems to be more selective. CEB are potent cerebrovascular vasodilating drugs especially after KCL induced vasoconstriction. This property appears less evident when vasoconstriction is achieved by agonist substances. CEB act selectively on cerebral vessels, an effect which prevents the occurrence of systemic arterial hypotension. However they greatly modify the cerebrovascular response to arterial CO2. Concerning the cerebrovascular response to arterial CO2. Concerning their potential benefits in brain ischemia, it is now well admitted that CEB are useful in subarachnoid hemorrhage. Several controlled and uncontrolled human studies have demonstrated the CEB potency in vasospasm prevention and in cerebral ischemic consequences. Nonetheless when the vasospasm is installed, the benefit of the CEB appears less evident. In focal cerebral ischemia, data are few and unclear suggesting a cautious prescription of CEB. Finally CEB seem to increase intracranial pressure in humans, although this effect depends on the underlying neurologic pathology.